CTNM
4:05 PM
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint Analyses of the data, including prespecified exploratory endpoints, are ongoing SAN DIEGO --(BUSINESS WIRE)--Sep. 14, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage
Trial Results • Phase 2Phase 2 MOONLIGHT-1 trial results Mon, Sep 14, 2026contineum-tx.com